Great Valley Advisor Group Inc. Buys 55,192 Shares of Novo Nordisk A/S (NYSE:NVO)

Great Valley Advisor Group Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 158.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 90,097 shares of the company's stock after buying an additional 55,192 shares during the quarter. Great Valley Advisor Group Inc.'s holdings in Novo Nordisk A/S were worth $7,749,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. M. Kulyk & Associates LLC boosted its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after acquiring an additional 119 shares during the period. Center for Financial Planning Inc. raised its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares in the last quarter. Exencial Wealth Advisors LLC raised its stake in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC raised its stake in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after purchasing an additional 126 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NVO. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Trading Up 4.5%

Novo Nordisk A/S stock traded up $3.04 during mid-day trading on Tuesday, hitting $70.39. The stock had a trading volume of 9,168,584 shares, compared to its average volume of 6,711,485. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The stock has a market capitalization of $315.88 billion, a PE ratio of 21.40, a P/E/G ratio of 0.90 and a beta of 0.65. The stock has a 50-day simple moving average of $66.07 and a two-hundred day simple moving average of $82.47.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.